Viracta Therapeutics, Inc. (VIRX)
USD 0.02
(14.44%)
USD 0.02
(14.44%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 38.37 Million USD | 9.99% |
| 2022 | 34.88 Million USD | 146.02% |
| 2021 | 14.18 Million USD | -84.99% |
| 2020 | 94.5 Million USD | 874.58% |
| 2019 | 9.69 Million USD | -14.42% |
| 2018 | 11.33 Million USD | -11.41% |
| 2017 | 12.79 Million USD | -42.41% |
| 2016 | 22.21 Million USD | 13.26% |
| 2015 | 19.6 Million USD | -35.59% |
| 2014 | 30.44 Million USD | -34.82% |
| 2013 | 46.7 Million USD | -23.5% |
| 2012 | 61.06 Million USD | 242.09% |
| 2011 | 17.84 Million USD | 41.54% |
| 2010 | 12.61 Million USD | 305.64% |
| 2009 | 3.1 Million USD | -50.6% |
| 2008 | 6.29 Million USD | -46.9% |
| 2007 | 11.85 Million USD | -4.98% |
| 2006 | 12.47 Million USD | -23.21% |
| 2005 | 16.24 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 30.25 Million USD | -21.16% |
| 2024 Q2 | 28.65 Million USD | -5.3% |
| 2023 Q3 | 36.42 Million USD | 0.98% |
| 2023 Q2 | 36.07 Million USD | 4.06% |
| 2023 Q1 | 34.66 Million USD | -0.63% |
| 2023 FY | 38.37 Million USD | 9.99% |
| 2023 Q4 | 38.37 Million USD | 5.34% |
| 2022 Q2 | 12.15 Million USD | -4.93% |
| 2022 Q1 | 12.78 Million USD | -9.87% |
| 2022 Q3 | 14.38 Million USD | 18.38% |
| 2022 FY | 34.88 Million USD | 146.02% |
| 2022 Q4 | 34.88 Million USD | 142.51% |
| 2021 FY | 14.18 Million USD | -84.99% |
| 2021 Q4 | 14.18 Million USD | 12.86% |
| 2021 Q3 | 12.56 Million USD | 8.49% |
| 2021 Q2 | 11.58 Million USD | 1.02% |
| 2021 Q1 | 11.46 Million USD | -87.87% |
| 2020 FY | 94.5 Million USD | 874.58% |
| 2020 Q1 | 9.4 Million USD | -3.05% |
| 2020 Q2 | 9.4 Million USD | -0.01% |
| 2020 Q4 | 94.5 Million USD | 2549.43% |
| 2020 Q3 | 3.56 Million USD | -62.05% |
| 2019 Q2 | 9.3 Million USD | -12.78% |
| 2019 Q3 | 9.31 Million USD | 0.12% |
| 2019 FY | 9.69 Million USD | -14.42% |
| 2019 Q1 | 10.66 Million USD | -5.85% |
| 2019 Q4 | 9.69 Million USD | 4.09% |
| 2018 Q4 | 11.33 Million USD | -7.8% |
| 2018 FY | 11.33 Million USD | -11.41% |
| 2018 Q3 | 12.29 Million USD | 2.03% |
| 2018 Q2 | 12.04 Million USD | 3.6% |
| 2018 Q1 | 11.62 Million USD | -9.09% |
| 2017 Q3 | 12.16 Million USD | -2.27% |
| 2017 FY | 12.79 Million USD | -42.41% |
| 2017 Q4 | 12.79 Million USD | 5.15% |
| 2017 Q2 | 12.44 Million USD | -42.31% |
| 2017 Q1 | 21.57 Million USD | -2.86% |
| 2016 FY | 22.21 Million USD | 13.26% |
| 2016 Q4 | 22.21 Million USD | -2.96% |
| 2016 Q1 | 21.46 Million USD | 9.44% |
| 2016 Q3 | 22.88 Million USD | -4.24% |
| 2016 Q2 | 23.9 Million USD | 11.37% |
| 2015 Q2 | 23.55 Million USD | -3.88% |
| 2015 Q4 | 19.6 Million USD | 1.82% |
| 2015 Q3 | 19.25 Million USD | -18.26% |
| 2015 FY | 19.6 Million USD | -35.59% |
| 2015 Q1 | 24.5 Million USD | -19.49% |
| 2014 Q2 | 43.87 Million USD | -4.76% |
| 2014 Q1 | 46.06 Million USD | -1.38% |
| 2014 FY | 30.44 Million USD | -34.82% |
| 2014 Q3 | 42.43 Million USD | -3.28% |
| 2014 Q4 | 30.44 Million USD | -28.26% |
| 2013 Q2 | 56.42 Million USD | -7.79% |
| 2013 FY | 46.7 Million USD | -23.5% |
| 2013 Q4 | 46.7 Million USD | -10.74% |
| 2013 Q3 | 52.33 Million USD | -7.25% |
| 2013 Q1 | 61.18 Million USD | 0.21% |
| 2012 Q2 | 23.94 Million USD | 7.71% |
| 2012 Q3 | 68.4 Million USD | 185.69% |
| 2012 FY | 61.06 Million USD | 242.09% |
| 2012 Q4 | 61.06 Million USD | -10.73% |
| 2012 Q1 | 22.23 Million USD | 24.54% |
| 2011 FY | 17.84 Million USD | 41.54% |
| 2011 Q4 | 17.84 Million USD | 126.97% |
| 2011 Q3 | 7.86 Million USD | -22.38% |
| 2011 Q2 | 10.13 Million USD | 22.41% |
| 2011 Q1 | 8.27 Million USD | -34.37% |
| 2010 Q2 | 5.59 Million USD | 57.88% |
| 2010 Q3 | 3.57 Million USD | -36.1% |
| 2010 Q4 | 12.61 Million USD | 253.02% |
| 2010 Q1 | 3.54 Million USD | 13.91% |
| 2010 FY | 12.61 Million USD | 305.64% |
| 2009 Q2 | 3.95 Million USD | -44.9% |
| 2009 Q1 | 7.18 Million USD | 14.21% |
| 2009 Q4 | 3.1 Million USD | -12.27% |
| 2009 Q3 | 3.54 Million USD | -10.51% |
| 2009 FY | 3.1 Million USD | -50.6% |
| 2008 Q2 | 11.91 Million USD | 17.36% |
| 2008 Q1 | 10.15 Million USD | -14.32% |
| 2008 FY | 6.29 Million USD | -46.9% |
| 2008 Q4 | 6.29 Million USD | -24.41% |
| 2008 Q3 | 8.32 Million USD | -30.15% |
| 2007 FY | 11.85 Million USD | -4.98% |
| 2007 Q3 | 11.64 Million USD | -8.41% |
| 2007 Q1 | 11.41 Million USD | -8.5% |
| 2007 Q2 | 12.71 Million USD | 11.36% |
| 2007 Q4 | 11.85 Million USD | 1.81% |
| 2006 FY | 12.47 Million USD | -23.21% |
| 2006 Q4 | 12.47 Million USD | -5.0% |
| 2006 Q1 | 12.98 Million USD | -20.06% |
| 2006 Q2 | 13.01 Million USD | 0.27% |
| 2006 Q3 | 13.12 Million USD | 0.84% |
| 2005 Q4 | 16.24 Million USD | -99.91% |
| 2005 Q3 | 17.87 Billion USD | 0.0% |
| 2005 FY | 16.24 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| America Great Health | 4.82 Million USD | -695.301% |
| Ampio Pharmaceuticals, Inc. | 2.37 Million USD | -1515.025% |
| Aridis Pharmaceuticals, Inc. | 38.92 Million USD | 1.423% |
| Biora Therapeutics, Inc. | 132.63 Million USD | 71.069% |
| Bio-Path Holdings, Inc. | 2.77 Million USD | -1280.82% |
| Better Therapeutics, Inc. | 23.84 Million USD | -60.947% |
| Calithera Biosciences, Inc. | 8.28 Million USD | -363.218% |
| Comera Life Sciences Holdings, Inc. | 9.97 Million USD | -284.723% |
| Gene Biotherapeutics, Inc. | - USD | -Infinity% |
| eFFECTOR Therapeutics, Inc. | 26.33 Million USD | -45.689% |
| Eloxx Pharmaceuticals, Inc. | 31.78 Million USD | -20.734% |
| Evelo Biosciences, Inc. | 69.43 Million USD | 44.734% |
| Evolutionary Genomics, Inc. | 7.94 Million USD | -382.947% |
| Finch Therapeutics Group, Inc. | 48.11 Million USD | 20.241% |
| Galera Therapeutics, Inc. | 157.32 Million USD | 75.609% |
| Innovation1 Biotech Inc. | 3.5 Million USD | -994.509% |
| Kiromic BioPharma, Inc. | 21.28 Million USD | -80.241% |
| Molecular Templates, Inc. | 31.17 Million USD | -23.105% |
| Navidea Biopharmaceuticals, Inc. | 12.51 Million USD | -206.618% |
| NexImmune, Inc. | 5.08 Million USD | -654.745% |
| Orgenesis Inc. | 35.53 Million USD | -7.986% |
| Panbela Therapeutics, Inc. | 16.51 Million USD | -132.395% |
| Point of Care Nano-Technology, Inc. | 266.41 Thousand USD | -14303.522% |
| PaxMedica, Inc. Common Stock | 2.29 Million USD | -1571.784% |
| Scopus BioPharma Inc. | 7.45 Million USD | -414.767% |
| Sorrento Therapeutics, Inc. | 494.5 Million USD | 92.24% |
| Statera Biopharma, Inc. | 22.67 Million USD | -69.22% |
| TRACON Pharmaceuticals, Inc. | 10.91 Million USD | -251.594% |
| Trevena, Inc. | 48.26 Million USD | 20.49% |
| Vaxxinity, Inc. | 30.94 Million USD | -24.008% |
| Vaccinex, Inc. | 5.94 Million USD | -545.793% |
| Vicapsys Life Sciences, Inc. | 1.96 Million USD | -1849.514% |
| ZIVO Bioscience, Inc. | 2.76 Million USD | -1289.542% |